Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib in Relapsed/Refractory Multiple Myeloma
NCT02140840Phase 2Withdrawn
- Sponsor
- University of Arkansas
- Start
- Mar 2015
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trametinib in multiple myeloma (MM), sponsored by University of Arkansas. Primary endpoint: Overall Response Rate at 28 days. Planned start Mar 2015; status: withdrawn.
02
Drugs
trametinib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02140840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02140840.